



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 19 June 2023 (#22)

Confirm your intent to apply **ASAP**, but not later than **60 days** before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take **4-18 months**, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Before starting your application, attend the **1) Generic Grant Writing Workshop** and then the **2) NIH Grant Writing Workshop**.

Important Notices

Successful [Sample Applications](#) Demonstrate Good Grantsmanship. One way to hone your grantsmanship skills is to examine well-written examples of successful grant applications. When you do so, remember that your application must also follow the latest official NIH [How To Apply](#) SF 424 instructions.

[NOT-AG-23-033](#) Notice of Pre-Application Webinar for [RFA-AG-24-036](#), "Measuring Financial Hardship Among People and Families Living with AD/DRD (R01 Clinical Trial Not Allowed)". The purpose of this Notice is to inform potential applicants that the National Institute on Aging (NIA) will hold a pre-application technical assistance live webinar regarding applications for [RFA-AG-24-036](#) on **June 21, 2023, from 2 PM to 3:30 PM Eastern Time**. Potential applicants interested in participating in the webinar should register [using this link](#). Webinar connection information will be provided to registered participants.

[NOT-AI-23-052](#) Request for Information (RFI): Inviting Comments and Suggestions on Updating the NIAID Strategic Plan for Tuberculosis Research. This notice is a time-sensitive Request for Information (RFI) inviting comments and suggestions on the update to NIAID's [Strategic Plan for Tuberculosis Research](#).

NIH seeks comments on any or all of, but not limited to, the following topics in Tuberculosis research:

- Significant research advances since 2018
- Significant research gaps and or barriers not identified in the strategic priorities above
- Impact of COVID-19 pandemic on Tuberculosis research
- Emerging scientific advances or techniques that may accelerate research related to the strategic priorities identified above
- Resources necessary to advance research in Tuberculosis related to the strategic priorities above

All comments must be submitted electronically on the submission website. Responses must be received by 11:59:59 PM (ET) on Aug 13, 2023.

Parent Announcements

[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates
Expiration Date: May 8, 2023 Modified Key Dates Expiration Date: May 8, 2024

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

[NOT-AI-23-045](#) **Understanding Mucosal Immunity Against Enteric Eukaryotic Pathogens to Advance Discovery of New Interventions.** The Notice of Special Interest (NOSI) invites applications to conduct research to better understand the basic biology and immunology associated with *Cryptosporidium* spp. (e.g., *Cryptosporidium parvum* and *Cryptosporidium hominis*), *Giardia duodenalis* (i.e., *Giardia lamblia*), and *Entamoeba histolytica*, including infection-induced mucosal immunity at the site of infection, leading to identification or discovery of new immune-mediated or host-directed interventions as countermeasures. This notice applies to application receipt dates on or after **October 5, 2023 and subsequent receipt dates through July 16, 2026**. Submit applications for this initiative using one of the notices of funding opportunities (NOFOs) or any reissues of these opportunities listed, through the expiration date of this notice.

[NOT-AI-23-048](#) **Promoting Research and Development of Vaccines Against Enteric.** The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID's interest in supporting vaccine research and development against enteric viruses. The scope of research supported is in three major topic areas: 1) address gaps in enteric virus research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; and 3) develop and advance new vaccine candidates to prevent infection or severe gastrointestinal disease. This NOSI encourages studies focusing on rotavirus, caliciviruses, astroviruses, and adenoviruses (*Human mastadenovirus F and G*). This notice applies to application receipt dates on or after **September 5, 2023 and subsequent receipt dates through July 16, 2026**. Submit applications for this initiative using one of the notices of funding opportunities (NOFOs) or any reissues of these opportunities listed, through the expiration date of this notice.

[NOT-DE-23-002](#) **Applications of Data Science in Translational Dental, Oral, and Craniofacial Research.** This Notice of Special Interest (NOSI) calls for a variety of data science-oriented projects focused on developing and using data and data science resources, methods, and tools for dental, oral, and craniofacial (DOC) research. Investigators and trainees who are currently active in DOC, non-DOC, and disease agnostic data science spaces are strongly encouraged to apply. An application can respond to any Notice of Funding Opportunity (NOFO), and subsequent reissues, listed under Related Announcements seeking support for research, research training, career development, product development, or conferences. Overall, the initiative will promote research, research training, and career development projects that develop and use state-of-the-art data science resources, methods, and tools in biomedical and behavioral DOC research spanning the full translational continuum from basic to clinical. In particular, applicants are strongly encouraged to develop and disseminate standards and tools to make retrospective and prospective biomedical and behavioral DOC data FAIR (findable, accessible, interoperable and reusable), use the data to discover disease prevention and treatment targets, and translate discoveries into evidence-based clinical applications. This notice applies to due dates **on or after August 8, 2023, and subsequent receipt dates through May 8, 2026**. Submit applications for this initiative using one of the notice of funding opportunity (NOFO) or any reissues of these announcements listed, through the expiration date of this notice.

[NOT-MH-23-255](#) **Clinical Studies of CNS Complications in People with HIV.** The goal of this initiative is to understand the heterogeneity of Central Nervous System (CNS) outcomes in people with HIV (PWH) and to support clinical research studies to aid in the identification/validation of actionable biosignatures of adverse CNS outcomes in people with HIV. Multidisciplinary research teams and collaborative alliances are encouraged but not required. Prospective applicants are **strongly encouraged to contact the Scientific Program Contacts** listed below **before preparing** an application to discuss the relevance of the proposed research to the Institute's research priorities. The use of human specimen resources from large NIH-funded HIV-related studies are encouraged. This notice applies to due dates on or after

September 7, 2023 and subsequent receipt dates through September 8, 2026. Submit applications for this initiative using one of the listed Notices of Funding Opportunities announcements (NOFOs) or any reissues of these announcements through the expiration date of this notice.

[NOT-MH-23-260](#) Eradication of HIV-1 from Central Nervous System Reservoirs. This Notice of Special Interest (NOSI) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. Prospective applicants are strongly encouraged to contact the Scientific Program Contacts listed before preparing an application to discuss the relevance of the proposed research to the Institute's research priorities. This notice applies to due dates on or after **September 7, 2023 and subsequent receipt dates through September 8, 2026.** Submit applications for this initiative using one of the listed Notices of Funding Opportunities (NOFOs) or any reissues of these announcement through the expiration date of this notice.

[NOT-MH-23-280](#) Neuropathogenesis of CNS Complications Associated with HIV. The goals of this NOSI are to stimulate further research on delineating the pathophysiology of HIV-1 associated Central Nervous System (CNS) complications in the setting of chronic viral suppression and antiretroviral therapy (ART). In addition, this NOSI also encourages research studies to aid in the identification/ validation of biomarkers with quantifiable readouts in domestic and international settings. Multidisciplinary research teams and collaborative alliances are encouraged but not required. Prospective applicants are **strongly encouraged to contact the Scientific Program Contacts** listed below **before preparing** an application to discuss the relevance of the proposed research to the Institute's research priorities. Applications to this NOSI are strongly encouraged to **integrate at least two levels of analysis** (e.g. behavior/cognition, neural circuits, genetics, molecular and cellular processes) and use approaches to study discrete neurobiologically-linked behavioral constructs ([RDoC Framework](#), [NIH Toolbox](#), and/or Neuro-QoL-based assessments). Use of **humanized animal models** and **brain organoids** that can mimic the pathophysiology of HIV infection are highly encouraged. Pathogenesis studies using model systems primarily focused on single viral gene products (such as HIV-1 Tat/gp120) in isolation and models of infection using chimeric HIV variants that do not represent the complete gamut of downstream neuropathogenic mechanisms related to HIV will **NOT** be supported under this NOSI. This notice applies to due dates on or after **September 7, 2023 and subsequent receipt dates through September 8, 2026.** Submit applications for this initiative using one of the listed Notices of Funding Opportunities announcements (NOFOs) or any reissues of these announcements through the expiration date of this notice.

Notice of Funding Opportunity (NOFO)

1. Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-207](#)

Type: R01

Application Due Date: **October 05, 2023 through to July 05, 2026.** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R01 mechanism, while the companion announcement [PAR-23-208](#) uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

2. Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-208](#)

Type:

Application Due Date: **October 16, 2023 through to July 16, 2026.** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R21 mechanism, while the companion [PAR-23-207](#) uses the R01 grant mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000, and no more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

3. Development of Software for Data Science in Infectious and Immune-Mediated Diseases Research (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-23-038](#)

Type: U01

Application Due Date: **October 11, 2023.** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this notice of funding opportunity (NOFO) is to solicit applications for the development of software to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for data science research on infectious and immune-mediated diseases (IID). Relevant IID data science research comprises, but is not limited to, computational methods to better understand disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment, and vaccines, aligned with the research mission of National Institute of Allergy and Infectious Diseases (NIAID). Development of software in various stages of maturity will be in scope for this NOFO, ranging from early-stage prototyping to later-stage hardening. Early-stage prototyping will enable others to use new computational algorithms, tools, or technologies through easy-to-use software products while hardening of existing software could improve usability and enable a broader user base to use the software for their research. Regardless of the development stage, the proposed work should result in a software product that can be re-used by the IID research community and that can be easily discovered through [FAIR](#) (Findable, Accessible, Interoperable and Reusable) compliant metadata.

Budget: NIAID intends to commit \$1,500,000 in FY24 to fund 2-3 awards. Direct costs are limited to \$300,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

4. BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-24-280](#)

Type: R01

Application Due Date: **June 07, 2024 through to February 08, 2027** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

Budget: Issuing IC and partner [components](#) intend to commit an estimated total of \$8 million to fund 6-9 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Research Development and Support Division (RDSD) & Grants Management Office (GMO)
Faculty of Medicine and Health Sciences
009 Kth Floor, Teaching Block, Tygerberg Campus.
Enquiries: [Christa](#)
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: [Lizél](#)
e: lizelk@sun.ac.za | t: +27 21 808 2105